share_log

Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12

Benzinga ·  Jul 18, 2023 06:56

Benchmark analyst Robert Wasserman initiates coverage on Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment